TABLE OF CONTENTS SYNOPSIS:
In this review we provide a general overview of key morphologic, molecular, and signaling mechanisms relevant to heart development before summarizing overall progress in the molecular genetic analyses of congenital heart defects (CHDs) and providing current recommendations for clinical application of genetic testing. CHDs represent the single largest cause of infant morbidity and mortality worldwide and are, consequently, a significant source of global economic burden. Advancements in genetic testing technologies have facilitated improved diagnostics and identification of novel genetic causes, which can encompass single-gene mutations, complex chromosomal abnormalities, submicroscopic rearrangements, or whole chromosome aneuploidies. While many CHDs occur in isolation, significant proportions are associated with extra-cardiac malformations as components of wider genetic syndromes.
For these reasons, genetic evaluation and counseling are considered integral components of risk assessment and clinical care.
heterogeneity of CHD is increasingly appreciated. Progress has been largely supported by improvements in genetic testing technology derived from worldwide efforts to accurately and economically characterize the full breadth of human genomic variation. The last fifteen years in particular have witnessed emergence and refinement of novel cytogenetic and sequencing technologies, which have proven to be enormously effective tools for both diagnosis and identification of novel CHD-causing genes. These advancements have led to an increasing need for cardiac care providers to be well versed in the molecular genetic origins of CHD and to have working knowledge of the benefits and limitations of available testing methods. In this review, we provide a general overview of key morphologic, molecular, and signaling mechanisms relevant to heart development before summarizing overall progress in the molecular genetic analyses of CHDs and current recommendations for clinical application of genetic testing. Particular emphasis is placed on the utility and limitations of chromosomal microarray analyses (CMAs) and on emerging clinical roles for whole exome sequencing (WES) and other next-generation sequencing (NGS) technologies.
KEY POINTS:
• Congenital heart defects (CHDs) are the largest contributor to worldwide infant morbidity and mortality.
• Known genetic causes encompass single-gene mutations, complex chromosomal abnormalities, submicroscopic rearrangements, and whole chromosome aneuploidies.
• Significant proportions of CHDs are associated with extra-cardiac malformations and/or occur as components of a genetic syndrome.
• Advancements in genetic testing technologies have facilitated improved diagnostics and identification of novel genetic causes of CHD.
• Genetic consultation and counseling is an integral component of risk assessment and clinical care.
Evaluation by a geneticist is essential when a possible syndrome is suspected.
INTRODUCTION:
The impact of CHDs is profound. With a traditionally cited incidence of 8 per 1000 live births (~1%), and a need for expert cardiologic intervention in 3 of every 1000 newborns 1 , CHDs are both the single largest cause of infant morbidity and mortality worldwide and a significant source of global economic burden 2, 3 . Taking into account very high rates of CHDs in spontaneous abortuses 4 , and subtle or subclinical abnormalities in another 1-2% of patients 5 , the true overall incidence of CHDs is undoubtedly much greater. While these figures effectively convey the large global clinical impact of CHDs, they fail to communicate both the enormous diversity of phenotypes among affected individuals and the emerging understanding of the complexity of genetic and developmental etiologies.
Research into the mechanisms that regulate heart development has advanced significantly in the last twenty years. Studies employing a diverse array of model organisms including mice, frogs, and zebrafish, have facilitated major insight into normal and abnormal cardiogenesis. Furthermore, systems biology approaches designed to assess functional convergence of causative CHD genes and associated transcriptional responders (genes with altered cardiac expression) have suggested that multiple CHD risk factors are more likely to act on different components of a common functional network than to directly converge on a common genetic or molecular target 6, 7 . These findings, coupled with an ever-expanding list of CHD-associated gene mutations 8 , chromosomal abnormalities 9 , environmental causes 10, 11 , and epigenetic insults 12, 13 hint at a significant complexity to both normal heart development and CHD pathogenesis. In the following section, we describe current understanding of the major embryologic events that shape the developing heart. We then provide a brief overview of key signaling and molecular concepts relevant to these developmental processes. Readers desiring additional details are directed to recent comprehensive reviews [14] [15] [16] [17] [18] [19] [20] [21] .
Overview of heart development:
Cell lineage is an important concept for heart development as distinct lineages support the development of specific cardiac compartments such that structural anomalies may result from dysregulation of a single cell lineage, multiple lineages, or specific inductive interactions between lineages. During the second and third weeks of human development, two mesodermal subpopulations, the first (FHF) and second (SHF) heart fields, contribute cells to the developing heart. While the FHF will ultimately contribute to the left ventricle and portions of the atria and right ventricle, the SHF supports development of the future outflow tract (OFT), ventricular septum, and the remainder of the atria and right ventricle 22 . Cells of the FHF originate in splanchnic mesoderm of the anterior lateral plate and in response to inductive signals from adjacent endoderm become the first cardiac precursors to differentiate 23 .
Gastrulation movements help to facilitate, positioning the cardiogenic mesoderm as bilateral folds alongside the prechordal plate. By 17-19 days, the cardiogenic folds coalesce anteriorly to form the cardiac crescent, a transient structure that will fuse and detach from the dorsal pericardial wall as a linear, bilaminar heart tube. Subsequent establishment of axial left-right asymmetries directs asymmetric growth and rightward looping of the heart tube, properly positioning the heart for future chamber and valve development. While these movements are occurring, cells from the SHF have already begun migrating from positions dorsal and posterior to the heart tube to support elongation of the arterial and venous poles. During weeks six and seven, an epithelial to mesenchymal transition populates the common atrioventricular canal and OFT with loose mesenchymal cell populations called endocardial cushions.
Mature valves arise through extensive cushion remodeling and become highly stratified into distinct layers. Meanwhile, neural crest cells delaminate from the dorsal neural tube and migrate into the developing OFT to support septation of the great vessels, as well as maturation of the aortic and pulmonary valves 24 . Significant cardiac contributions are also made by cells of the proepicardium, which originate from venous coelomic mesothelium and support development of the future epicardium and coronary vasculature 25 . As development nears completion, the heart is refined into a muscular, fourchambered organ capable of regulating incoming and outgoing blood flow by way of divided inflow and outflow tracts and mature valve and conduction systems.
Complex signaling and transcriptional networks regulate heart development:
These embryonic events are tightly regulated by an extensive array of signaling pathways and transcription factors. Several recent publications have reviewed the roles of these networks throughout all major stages of cardiac development [15] [16] [17] [18] 26 . Therefore, the intent here will not be to reproduce these comprehensive works, but rather to highlight general mechanisms.
Every major developmental pathway contributes in some capacity to heart development ( Table   1) , often through extensive cross-talk with other signals or molecular factors. The impact of a particular signal can vary dramatically as development proceeds, operating positively at one stage and negatively at another. For example, Bmp signaling is required to induce differentiation of early cardiac progenitors, but is inhibited at later stages by Smad6a to permit Tbx2-and Tbx20-mediated chamber development 27 .
Similarly, mouse studies have demonstrated that Wnt signals are critical for early cardiac precursor induction and proliferation, but later become inhibitory 28, 29 . As previously mentioned, a diverse array of cardiac transcription factors acts in concert with these signals to specify, differentiate, and pattern the developing heart. Clinical genetic testing is available for many of these factors and is summarized in Table 2 . The resulting web of interactions supports a highly complex milieu in which individual or multiple risk factors can act to disrupt normal heart morphogenesis. An ideal example is provided by the cardiac transcription factor, Nkx2.5, which has key functions in regulating proliferation of SHF cells through repression of Bmp2 signaling 30 and in conduction system development 31 . Nkx2.5 also physically and functionally interacts with the major cardiac transcription factors Gata4 32 , Tbx5 33 , and Mef2c 34 , each of which forms additional unique and shared connections with other molecular, genetic, and signaling components ( Figure 1 ). Such networks also hint at "common disease-common variant" hypotheses and the implication that some CHD phenotypes may result from additive effects of multiple low-effect susceptibility alleles. Following identification of two disease-associated haplotypes in large Caucasian and African American cohorts 35 , the SHF marker / Lim-homeodomain transcription factor, ISL1, has emerged as a possible susceptibility candidate. Although the pathogenicity of at least one of the reported variants remains uncertain 36, 37 , these studies highlight a growing recognition of the potential for common alleles to contribute to CHD pathogenesis.
GENETICS AND RECURRENCE:
Contemporary advancements in medical care, surgical interventions, and diagnostics have contributed to a well-characterized decrease in patient mortality and concomitant increase in CHD prevalence among patients of reproductive age [38] [39] [40] . Recent analyses indicate that adults now constitute roughly two-thirds of the CHD population, representing a nearly 60% increase in CHD prevalence among adult patients since the year 2000 38 . The fact that the greatest increase in CHD prevalence has occurred among the 18-to 40-year-old demographic 38 has clear implications for heritability.
Large-scale epidemiologic studies suggest that a genetic or environmental cause for CHD is identifiable in approximately 20-30% of cases [41] [42] [43] . Known genetic causes are extremely heterogeneous, encompassing not only mutations in cardiac-relevant genes, but also more complex chromosomal abnormalities, submicroscopic duplications/deletions, and whole chromosome aneuploidies ( Table 3) . As genetic testing technologies have evolved to offer higher resolutions and greater diagnostic yields than those provided by conventional chromosomal analyses, copy number variants (CNVs) have emerged as important causes of both syndromic and non-syndromic CHDs 9 . Moreover, an increasing recognition of contributing environmental 10, 11 and epigenetic 12, 13 factors has revealed a previously unanticipated breadth to CHD etiology. Families with Mendelian inheritance have been useful for identifying monogenic causes, although mutations in identified genes have been infrequently detected in unrelated patient cohorts 44 . Autosomal dominant, autosomal recessive, and X-linked inheritance patterns have all been reported, often in the context of additional non-cardiac malformations or syndromic disease, and each pose unique recurrence risks for affected families (Table 4) . Improvements in diagnostic fidelity offered by chromosomal microarray analysis (CMA) and fluorescence in-situ hybridization (FISH) have additionally facilitated re-diagnosis of many patients with syndromic disease previously thought to have isolated CHD 45 . Establishment of an accurate genetic diagnosis is of critical importance, holding significant implications for not only medical management and long-term follow-up, but also for communication of relevant reproductive risks and family planning.
In general, recurrence estimates are more precise for syndromic than for isolated CHDs as inheritance patterns for many CHD-associated genetic conditions are already well characterized (Table   4 ). For dominantly inherited conditions, such as Noonan or Holt-Oram syndromes, individual recurrence risks for offspring with the syndrome is 50%. Genetic testing is also indicated for male offspring in families with X-linked heterotaxy caused by mutations in ZIC3, as they also have a 50% recurrence risk.
Importantly not all patients with a particular syndrome will present with associated heart defects and the proportion that do can vary considerably depending on the specific diagnosis ( Table 4) . The presence or severity of a CHD in a parent is also not predictive of the risk for offspring. The prevalence of CHDs in a population caused by a particular syndrome ultimately depends on the likelihood of affected individuals reaching reproductive age and the new mutation rate. Consequently, despite having relatively high rates of associated CHDs, patients with lethal conditions such as Edwards Syndrome (Trisomy 18) or Patau Syndrome (Trisomy 13) contribute less to overall population CHD burden than patients with less severe, but more prevalent conditions.
Recurrence risks for isolated CHDs can be difficult to assign. This is especially true when the disease phenotype is complicated by reduced penetrance and variable expressivity, both of which are common. Indeed, dramatically different CHD phenotypes can be exhibited by patients with identical mutations, even among members of the same family. Nevertheless, consistent evidence of familial clustering and high heritability of isolated CHDs indicate that a strong genetic component exists, even for defects occurring without an obvious mode of inheritance [46] [47] [48] [49] . Increased rates of CHDs among offspring of consanguineous unions have been noted in several populations and are commonly attributed to autosomal recessive mutations in associated disease genes (reviewed in Shieh et al 50 ). Long-standing CHD models consider a large subset of CHDs to be multifactorial in origin, resulting from combined interaction of a number of distinct environmental and genetic factors 51 . Several large-scale epidemiological studies have examined rates of recurrence among first degree relatives of patients with isolated CHDs and collectively suggest an overall risk of 5-10% for any CHD when either one parent or more than two siblings are affected [52] [53] [54] . This figure reduces to ~3% with a single affected child. Risk estimates for individual defects vary, but are generally estimated in the range of 2-6%, with higher risk afforded to children of affected mothers (Table 5 ). These figures are low relative to CHDs with demonstrable monogenic inheritance, but can still have potentially important implications, particularly with respect to future reproductive decision-making and prospective screening of presumably unaffected family members.
DIAGNOSTIC EVALUATION:
Genetic testing algorithm for CHD:
Genetic testing practices for CHDs have yet to be standardized in many centers and recommendations incorporating newer genetic testing technologies are, at present, poorly represented in the literature. In addition, there is evidence that genetic testing is frequently underutilized in infants with CHD 55, 56 . Nevertheless, the importance of genetic evaluation of patients with CHD has been emphasized in a position statement from the American Heart Association 57 , which cites four specific reasons to pursue testing:
(1) there may be other important organ system involvement, (2) there may be prognostic information for clinical outcomes, (3) there may be important genetic reproductive risks the family should know about; and (4) there may be other family members for whom genetic testing is appropriate.
In Figure 2 , we suggest a genetic testing algorithm that could be instituted in infants with CHD to provide a more comprehensive and standardized approach. This algorithm is derived from extensive clinical experience and has been used at our institution since 2009. These recommendations were explicitly created to guide cardiac care practitioners in determining appropriate genetic testing and referral strategies for cardiac intensive care unit (CICU) patients. Practitioners should evaluate guidelines most appropriate for their institution with a goal of practicing evidence-based medicine. In our center, geneticists consult patients with syndromic or suspected syndromic CHD and genetic counselors facilitate genetic testing in patients with apparently isolated CHD for whom testing is indicated and expedite appropriate cardiac screening in first degree relatives. Ongoing multicenter registries aimed at refining the interpretation of clinical CMA findings, such as the Clinical Genome Project and the Cytogenomics of Cardiovascular Malformations Consortium, will continue to improve the diagnostic yield and interpretation of abnormal CMA in patients with CHD.
Genetic services and counseling:
Recent surveys of adult CHD populations have demonstrated that a majority of patients lack proper understanding of their personal recurrence risks, but that provision and recall of genetic information can be significantly improved by incorporating genetic services into routine cardiovascular care 58, 59 . Genetic counselors skilled in cardiovascular genetics have, consequently, become an invaluable clinical asset, helping to not only provide accurate recurrence risks, but also to obtain family and medical histories, facilitate appropriate genetic testing, interpret test results, make necessary subspecialty referrals, and provide attendant psychosocial support for patients and their families 60 . The importance of the cardiologist in promoting genetic services cannot be understated: most patients first hear about the possibility of genetic consultation from their cardiologist and a majority of these patients retroactively view the resulting genetics appointments positively 58, 59 . These findings are particularly relevant in light of results from a non-scientific poll recently conducted at the 21st Annual International Adult Congenital Heart Disease (ACHD) Course which suggest that only 18% of ACHD practitioners regularly refer their patients for genetic evaluation and that only 25% regularly work alongside genetic counselors and clinical geneticists 60 . Continued integration of genetic professionals into existing and new cardiovascular programs will undoubtedly help to improve utilization of increasingly comprehensive and affordable genetic services.
GENETIC TESTING AND EMERGING TECHNOLOGIES:
Chromosomal analyses and copy number variation:
Genetic testing technologies have progressed considerably in recent years with novel sequencing and chromosome-based methods improving both the speed and breadth of available testing options.
Although karyotyping remains the gold standard for diagnosis of aneuploidies and other large chromosomal abnormalities, cytogenetic methods such as FISH and CMA have proven invaluable in identifying microdeletion and duplication syndromes resulting from abnormalities too small to be detected by conventional chromosomal analyses (Table 6 ). These developments are significant: an ever-growing body of studies indicate that pathogenic CNVs are a major cause of CHDs, occurring in 3-25% of patients with extra-cardiac abnormalities and in 3-10% of patients with isolated heart defects (reviewed in Lander et al. 9 ). In practice, the relatively limited resolutions of karyotyping and FISH have rendered them insufficient to detect a genetic cause in the majority of patients with CHDs of uncertain etiology 55 and in nearly half of all patients with syndromic CHD 61 . Therefore, use of CMA as a higher fidelity option for firstline CHD genetic testing has been recommended, particularly when extra-cardiac features are present and a suspected diagnosis is lacking 61 . This opinion has been strongly supported by additional clinical and research studies assessing diagnostic yields in selected cohorts 55, 56, [62] [63] [64] [65] . In our retrospective analysis, CMA testing detected cytogenetic abnormalities of clinical or unknown significance in 35/121 (29%) infants with CHD 56 , representing rates on par with those observed in patients undergoing testing for intellectual disability 66, 67 , for which CMA is already a first-line diagnostic test. Because most causal CNVs in patients with syndromic CHD are readily detectable by even low-resolution CMAs, and because significant increases in CMA resolution may not always translate to higher diagnostic yields 68 , physicians encountering patients with potentially syndromic phenotypes, but normal CMA results, would be prudent to rule out the possibility of a previously missed monogenic cause. Supporting this recommendation, Breckpot et al. 55 identified 7% of patients in their cohort with normal CMA results who were later found to have a singlegene disorder on follow-up.
Next-generation sequencing and whole exome analysis:
Genetic technologies are advancing at such a rapid pace that keeping abreast of methodological advancements and emerging clinical applications has become both more essential and more challenging than ever before. Arguably the most significant development in recent years has been the advent of massively parallel next-generation sequencing (NGS) technologies, which encompass an assortment of commercially and methodologically distinct services that share similar foundations in repeated sequencing of DNA fragments (reviewed in Dorn et al. 69 , with a focus on CHD). Millions of individual sequences ("reads") are generated in simultaneous reactions and are subsequently aligned to form a completed sequence. These techniques facilitate considerably higher depths of coverage, faster turnaround times, and increased cost-effectiveness when compared to traditional capillary-based sequencing methods 70, 71 . Although Sanger sequencing remains the gold standard for targeted analyses of specific genes or familial mutations, it requires a priori knowledge of causative disease genes or sequences and does not contribute to novel gene discovery. Additionally, most gene panels are diseasespecific, necessitating implementation of large numbers of distinct assays. Conversely, like CMA, NGS approaches provide greater diagnostic utility for suspected genetic disease of uncertain etiology and for genetically heterogeneous conditions stemming from mutations in larger numbers of causative loci. One of the biggest benefits of this technology has been its scalability -both to large-scale whole genome/exome analyses and to smaller gene-specific targeted studies. This flexibility has initiated a paradigm shift towards adoption of NGS in both clinical and research settings and has, even in its relative infancy, greatly benefited novel disease gene discovery and patient diagnosis [72] [73] [74] [75] [76] .
Nowhere is this shift more apparent than in the increased clinical implementation of whole exome sequencing (WES) 73 . In contrast to whole genome sequencing (WGS), which interrogates every base in the genome, WES specifically targets protein-encoding genomic regions and makes the implicit assumption that a significant proportion of uncharacterized genetic disease can be explained by sequence variation in coding DNA. This assumption is reasonable for many inherited conditions as most mutations resulting in Mendelian disease have been traditionally detected in protein-coding regions [77] [78] [79] . In addition, our current ability to interpret the functional significance of variants in non-coding regions is relatively primitive 57 . Importantly, WES has been demonstrated to be both robust and cost-effective 80 , necessitating only 5% of the total sequencing required by GWS 81 . Adoption of WES has consequently been swift: since its clinical debut in 2011, most major genetic centers have established WES as a testing option for patients with complex phenotypes for whom traditional single and multi-gene panels were unrevealing, prohibitively expensive, or otherwise unavailable. Although these programs are still young, initial studies have reported deleterious mutation detection rates in the range of 20-50% 72, 82, 83 , indicating significant potential for high diagnostic yields. WES has already been used successfully to identify genetic defects associated with a diverse spectrum of CHDs [84] [85] [86] [87] . Interpretation of detected variants, however, remains a major challenge as WES identifies, on average, 12,000 unique coding variants per exome sequenced 88 and potentially pathogenic variants are observed even in apparently healthy individuals [89] [90] [91] .
It is expected that reporting laboratories will perform a thorough literature review for all variants of potential clinical relevance and properly classify each as having known or uncertain significance.
While WES is clearly beneficial in multiple settings, its use as a first-tier test has generated debate, with concerns raised over not only interpretation and reporting of clinically relevant mutations, but also return of incidental findings, availability of insurance coverage, and cost effectiveness relative to existing multi-gene panels 72, 92 . Thus, it is important that care providers familiar both with the strengths and limitations of WES and its applicability to the patient's phenotype(s) be involved in facilitating testing.
It is anticipated that the already widespread application of WES will lead to improvements in existing technologies, decreasing overall costs and increased insurance coverage.
Future developments:
To date, clinical application of NGS has largely been restricted to analysis of genomic variation.
Nevertheless, the same technologies employed for DNA-based analyses can be used to interrogate a variety of other disease-relevant processes, including RNA expression, alterations in splicing, epigenetic regulation, and protein-nucleotide interactions (eg: transcription factor binding) 93 . These applications hold considerable future diagnostic and clinical potential and are already providing great utility for investigators applying comprehensive system-based approaches to the study of CHD 94, 95 . The recognition that multiple independent insults are likely to contribute to at least a subset of CHD phenotypes indicate that systemsbased approaches will be necessary to understand CHD risk factor networks and properly contextualize many genetic testing results, particularly in the absence of extra-cardiac features or clear syndromic diagnoses.
SUMMARY:
The field of CHD genetics is progressing at a rapid pace. The last decade in particular has witnessed unprecedented improvements in genetic testing technologies that have greatly assisted gene discovery and helped to reshape standards of patient care. These trends are likely to continue as testing costs continue to decline and genetic services become further integrated into new and existing cardiovascular programs. With the functional significance of much of the genome still undefined and the mechanisms driving both normal and abnormal heart development incompletely understood, interpretation and reporting of clinically relevant mutations will remain a major challenge for the foreseeable future. Accordingly, clinical geneticists and genetic counselors will need to play increasingly 
BEST PRACTICES: Best Practices Box
What is the current practice? Genetic Testing in Congenital Heart Disease:
• Genetic testing practices for CHDs have yet to be standardized in many centers.
• Recommendations incorporating newer genetic testing methods are poorly represented in the literature.
• Genetic testing is frequently underutilized for infants with CHD.
Genetic Testing Options:
• Karyotyping is the gold standard for diagnosis of aneuploidies and other large chromosomal abnormalities.
• Chromosomal microarray (CMA) and fluorescence in situ hybridization (FISH) permit identification of microdeletion and duplication syndromes resulting from abnormalities too small to be detected by conventional chromosome analyses.
• Sanger sequencing is the gold standard for targeted molecular analysis of specific genes or familial mutations. Gene panels are available for many CHD-associated syndromes, but are limited by knowledge of causative disease genes.
What changes in current practice are likely to improve outcomes?
• Continued integration of genetic testing services into cardiovascular practice will improve diagnostic and prognostic accuracy and will support risk assessment and family planning initiatives.
• Emerging next generation sequencing (NGS) technologies promise to greatly benefit patient diagnosis and gene discovery efforts.
Is there a Clinical Algorithm?
• Our proposed genetic testing algorithm is presented in Figure 2 .
• In our center, geneticists consult patients with known or suspected syndromic CHD and genetic counselors facilitate genetic testing in patients with apparently isolated CHD and expedite appropriate screening in first degree relatives.
Major Recommendations:
Genetic testing and referral decisions should be determined based on the nature of the cardiac defect:
1. Patients with defects suggesting a common chromosomal aneuploidy should undergo karyotyping and FISH testing. The patient should be referred for further genetic evaluation. 2. Patients with multiple congenital anomalies, neurological findings, developmental delay, and/or dysmorphic features should also be referred for further genetics evaluation. 3. Depending on the level of suspicion, patients with conotruncal defects should undergo CMA and/or targeted FISH testing for 22q11.2 deletion syndrome. 4. A detailed pedigree should be obtained and CMA testing should be pursued for patients with apparently non-syndromic LVOTO, RVOTO, AVSD, heterotaxy, or other complex defects. Abnormal test results warrant referral for further genetics evaluation.
Rating for the Strength of the Evidence:
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Summary:
• Improvements in genetic testing technologies have assisted gene discovery and helped to reshape standards of patient care. These trends are expected to continue as testing costs decline and genetic services become further integrated into new and existing cardiovascular programs. "GATA4, NKX-5, TBX5, and MEF2C" were used as query terms and results were weighted towards "biological process". To maximize readability, output was restricted to 20 related genes. Cardiac mesoderm induction Cardiac progenitor specification SHF / OFT development Abbreviations: A-P = anterior-posterior, AV = atrioventricular, BMP = bone morphogenetic protein, EC = endocardial cushion, EGF = epidermal growth factor, ERK = extracellular signal-regulated kinase, FGF = fibroblast growth factor, L-R = left-right, MAPK = mitogen-activated protein kinase, NCC = neural crest cell, OFT = outflow tract, RA = retinoic acid, SHF = second heart field, TGF-β = transforming growth factor-beta, VEGF = vascular endothelial growth factor, Wnt = wingless type [52] [53] [54] except where otherwise noted. NR = not reported/insufficient data Merged cells indicate recurrence when one parent is affected, irrespective of gender, and are used in the absence of gender-stratified risks. Abbreviations: ASD = atrial septal defect, AS = aortic stenosis, AVSD = atrioventricular septal defect, CoA = coarctation of the aorta, EA = Ebstein's Anomaly, HLHS = hypoplastic left heart syndrome, L-TGA = congenitally corrected transposition of the great arteries, PDA = patent ductus arteriosus, PA = pulmonary atresia, PS = pulmonary stenosis, TA = tricuspid atresia, TGA = transposition of the great arteries, TOF = Tetralogy of Fallot, TrA = truncus arteriosus, VSD = ventricular septal defect Abbreviations: aCGH = array comparative genomic hybridization, CMA = chromosome microarray analysis, CNVs = copy number variants, FISH = fluorescence in situ hybridization, SNPs = single nucleotide polymorphisms, WES = whole exome sequencing, WGS = whole genome sequencing
